Clinical Trial Update: Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating dabigatran etexilate for extended prevention of venous thromboembolism after hip replacement; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Thromboembolism, Arthroplasty, Replacement, Hip | Phase 3 | Status: COMPLETED | Results posted: 2010-12-20